Botanical immunodrugs: Scope and opportunities

Drug Discovery Today

Volumn 10, Issue 7, 2005, Pages 495-502

  Patwardhan, Bhushan ^a   Gautam, Manish ^a  

^a UNIVERSITY OF PUNE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; ANTINEOPLASTIC AGENT; APOCYNIN; ARTEMISININ; BERBERINE; CYTOKINE; DNA VACCINE; DOXORUBICIN; ELEUTHEROCOCCUS SENTICOSUS EXTRACT; GAMMA INTERFERON; GINSENG EXTRACT; GLYCYRRHIZIC ACID; INTERLEUKIN 2; LEVAMISOLE; MATRINE; METHISOPRINOL; PEGINTERFERON; PENTOXIFYLLINE; PICRORHIZA KURROA EXTRACT; PIPERINE; RIBAVIRIN; SINOMENINE; THALIDOMIDE; TRIPTOLIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VISCUM ALBUM LECTIN; WITHAFERIN A; WITHANIA SOMNIFERA EXTRACT;

ACTIVE IMMUNIZATION; ANTINEOPLASTIC ACTIVITY; CANCER; CELL PROTECTION; DELTA AGENT HEPATITIS; DRUG ACTIVITY; DRUG TARGETING; ECHINACEA; GLYCYRRHIZA GLABRA; HEPATITIS B; HEPATITIS C; HERBAL MEDICINE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; LIVER CIRRHOSIS; NONHUMAN; PASSIVE IMMUNIZATION; REVIEW; UNCARIA TOMENTOSA; WITHANIA SOMNIFERA;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; INFECTION; INFLAMMATION; MEDICINE, TRADITIONAL; NEOPLASMS; PHYTOTHERAPY; PLANT PREPARATIONS; SYSTEMS BIOLOGY;

EID: 16844378307     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03357-4     Document Type: Review

References (94)

1. Oberholzer A., et al. Cytokine signaling-regulation of the immune response in normal and critically ill states. Crit. Care Med. 28:2000;N3-N12
2. Nelson R.P. Jr, Ballow M. Immunomodulation and immunotherapy: drugs, cytokines, cytokine receptors, and antibodies. J. Allergy Clin. Immunol. 111:2003;S720-S743
3. Geissler M., Weth R. Immunotherapy: new insights. Schweiz. Rundsch. Med. Prax. 91:2002;2236-2246
4. Whelan M., et al. Cancer immunotherapy: an embarrassment of riches. Drug Discov. Today. 8:2003;253-258
5. Chada S., et al. Cytokine- and chemokine-based gene therapy for cancer. Curr. Opin. Mol. Ther. 5:2003;463-474
6. Mihich E., Ehrke M.J. Anticancer drugs plus cytokines: immunodulation based therapies of mouse tumors. Int. J. Immunopharmacol. 22:2000;1077-1081
7. Marriot J.B., et al. Thalidomide as an emerging immunotherapeutic agent. Immunol. Today. 20:1999;538-540
8. Van Der Meijden A.P.M. Non-specific immunotherapy with bacille Canette-Guérin (BCG). Clin. Exp. Immunol. 123:2001;179-180
9. Buchwald U.K., Pirofski L. Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. Curr. Pharm. Des. 9:2003;945-968
10. Kuhen K.L., Samuel C.E. Mechanism of interferon action: functional characterization of positive and negative domains that modulate transcriptional activation of the human RNA-dependent protein kinase PKR promoter. Virology. 254:1999;182-195
11. Glue P., et al. Pegylated interferon- alpha-2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Ther. 68:2000;556-567
12. Blackwell T.S., Christman J.W. Sepsis and cytokines: current status. Br. J. Anaesth. 77:1996;110-117
13. Fontaine H., et al. Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa. Lancet. 356:2000;41
14. Schulze-Koops H., et al. What we have learned from trials of immunomodulatory agents in rheumatoid arthritis: Future directions. Drugs Today (Barc). 35:1999;327-351
15. Cobbold S.P., et al. Reprogramming the immune system for tolerance with monoclonal antibodies. Semin. Immunol. 2:1990;377-387
16. Kavanaugh A.F., et al. A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J. Rheumatol. 23:1996;1338-1344
17. Sfikakis P.P., Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr. Opin. Rheumatol. 15:2003;380-386
18. Paleolog E. The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis. Expert Opin. Investig. Drugs. 12:2003;1087-1095
19. Palladino M.A., et al. Anti-TNF-alpha therapies: the next generation. Nat. Rev. Drug Discov. 2:2003;736-746
20. Cope A.P. Studies of T-cell activation in chronic inflammation. Arthritis Res. 4:(Suppl. 3):2002;S197-S211
21. Davis L.S., et al. Rheumatoid synovial CD4+ T cells exhibit a reduced capacity to differentiate into IL-4-producing T-helper-2 effector cells. Arthritis Res. 3:2001;54-64
22. Adorini L., et al. Manipulation of the Th1/Th2 cells balance: an approach to treat human autoimmune diseases? Autoimmunity. 23:1996;53-68
23. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature. 430:2004;257-263
24. Ghebrehiwet B. CC1q-R (calreticulin) and gC1q-R/p33: ubiquitously expressed multi-ligand binding cellular proteins involved in inflammation and infection. Mol. Immunol. 41:2004;173-183
25. Burke J.R. Targeting I kappa B kinase for the treatment of inflammatory and other disorders. Curr. Opin. Drug Discov. Devel. 6:2003;720-728
26. Maini R., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 354:1999;1932-1999
27. Kim J.J. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-g, or IL-4 gene adjuvants. Vaccine. 19:2001;2496-2505
28. Marciani D.J. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today. 8:2003;934-943
29. Burdin N., et al. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs. 18:2004;79-93
30. Brown G.D., Gordon S. Fungal B glucans and mammalian immunity. Immunity. 19:2003;311-315
31. Mossman T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7:1989;145-173
32. Singh V.K., et al. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol. Res. 20:1999;147-161
33. Giese K., et al. Unravelling novel intracellular pathways in cell-based assays. Drug Discov. Today. 7:2002;179-186
34. Roger P.M., et al. Revival of the regulatory T cell: New targets for drug development. Drug Discov. Today. 9:2004;310-316
35. Plaeger S.F. Clinical immunology and traditional herbal medicines. Clin. Diagn. Lab. Immunol. 10:2003;337-338
36. Dai Y., et al. T-cell-immunity-based inhibitory effects of orally administered herbal medicine juzen-taiho-to on the growth of primarily developed melanocytic tumors in RET-transgenic mice. J. Invest. Dermatol. 117:2001;694-701
37. Patwardhan B., et al. Ayurveda and natural products drug discovery. Curr. Sci. 86:2004;789-799
38. Rollinger J.M., et al. Combining ethnopharmacology and virtual screening for lead structure discovery: COX-inhibitors as application example. J. Chem. Inf. Comput. Sci. 44:2004;480-488
39. Patwardhan B. Ayurveda: the 'designer' medicine: a review of ethnopharmacology and bioprospecting research. Indian drugs. 37:2000;213-227
40. Rege N.N., et al. Adaptogenic properties of six rasayana herbs in ayurvedic medicine. Phytother. Res. 13:1999;275-291
41. Yoshikawa M., et al. Effects of glycyrrhizin on immune-mediated cytotoxicity. J. Gastroenterol. Hepatol. 12:1997;243-248
42. Sekizawa T., et al. Glycyrrhizin increases survival of mice with herpes simplex encephalitis. Acta Virol. 45:2001;51-54
43. Utsunomiya T., et al. Glycyrrhizin improves the resistance of MAIDS mice to opportunistic infection of Candida albicans through the modulation of MAIDS-associated type 2 T cell responses. Clin. Immunol. 95:2000;145-155
44. Cinatl J., et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 361:2003;2045-2046
45. Fujisawa Y., et al. Glycyrrhizin inhibits the lytic pathway of complement-possible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis. Microbiol. Immunol. 44:2000;799-804
46. Jo E.H., et al. Modulations of the Bcl-2/Bax family were involved in the chemopreventive effects of licorice root (Glycyrrhiza uralensis Fisch) in MCF-7 human breast cancer cell. J. Agric. Food Chem. 52:2004;1715-1719
47. Barfod L., et al. Chalcones from Chinese liquorice inhibit proliferation of T cells and production of cytokines. Int. Immunopharmacol. 2:2002;545-555
48. Baltina L.A. Chemical modification of glycyrrhizic acid as a route to new bioactive compounds for medicine. Curr. Med. Chem. 10:2003;155-171
49. Abe M., et al. Glycyrrhizin enhances interleukin-10 production by liver dendritic cells in mice with hepatitis. J. Gastroenterol. 38:2003;962-967
50. Reinhard K.H. Uncaria tomentosa (Willd.) D.C.: cat's claw, una de gato, or saventaro. J. Altern. Complement. Med. 5:1999;143-151
51. Wurm M., et al. Pentacyclic oxindole alkaloids from Uncaria tomentosa induce human endothelial cells to release a lymphocyte-proliferation-regulating factor. Planta Med. 64:1998;701-704
52. Winkler C., et al. In vitro effects of two extracts and two pure alkaloid preparations of Uncaria tomentosa on peripheral blood mononuclear cells. Planta Med. 70:2004;205-210
53. Sandoval-Chacon M., et al. Anti-inflammatory actions of cat's claw: the role of NF-kappa B. Aliment. Pharmacol. Ther. 12:1998;1279-1289
54. Sandoval M., et al. Cat's claw inhibits TNF-α production and scavenges free radicals: role in cytoprotection. Free Radic. Biol. Med. 29:2000;71-78
55. Mur E., et al. Randomized double-blind trial of an extract from the pentacyclic alkaloid-chemotype of Uncaria tomentosa for the treatment of rheumatoid arthritis. J. Rheumatol. 29:2002;678-681
56. Sheng Y., et al. Treatment of chemotherapy-induced leucopoenia in a rat model with aqueous extract from Uncaria tomentosa. Phytomedicine. 7:2000;137-143
57. Sheng Y., et al. Induction of apoptosis and inhibition of proliferation in human tumor cells treated with extracts of Uncaria tomentosa. Anticancer Res. 18:1998;3363-3368
58. Stimpel M., et al. Macrophage activation and induction of macrophage cytotoxicity by purified polysaccharide fractions from the plant Echinacea purpurea. Infect. Immun. 46:1984;845-849
59. Anonymous. Echinacea monographM. Altern. Med. Rev. 6:2001;411-414
60. Melchart D., et al. Results of five randomized studies on the immunomodulatory activity of preparations of Echinacea. J. Altern. Complement. Med. 1:1995;145-160
61. Henneicke-von Z.H., et al. Efficacy and safety of a fixed combination phytomedicine in the treatment of the common cold (acute viral respiratory tract infection): results of a randomised, double-blind, placebo-controlled, multicentric study. Curr. Med. Res. Opin. 15:1999;214-227
62. Mishra L.C., et al. Scientific basis for the therapeutic use of Withania somnifera (Ashwagandha): a review. Altern. Med. Rev. 5:2000;334-346
63. Diwanay S., et al. Immunoprotection by botanical drugs in cancer chemotherapy. J. Ethnopharmacol. 90:2004;49-55
64. Prakash J., et al. Withania somnifera root extract prevents DMBA-induced squamous cell carcinoma of skin in Swiss albino mice. Nutr. Cancer. 42:2002;91-97
65. Jayaprakasam B., et al. Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves. Life Sci. 74:2003;125-132
66. Iuvone T., et al. Induction of nitric oxide synthase expression by Withania somnifera in macrophages. Life Sci. 72:2003;1617-1625
67. Davis L., Kuttan G. Effect of Withania somnifera on cell-mediated immune responses in mice. J. Exp. Clin. Cancer Res. 21:2002;585-590
68. Davis L., Kuttan G. Immunomodulatory activity of Withania somnifera. J. Ethnopharmacol. 71:2000;193-200
69. Ziauddin M., et al. Studies on the immunomodulatory effects of Ashwagandha. J. Ethnopharmacol. 50:1996;69-76
70. Gautam M., et al. Immune response modulation to DPT vaccine by aqueous extract of Withania somnifera in experimental system. Int. Immunopharmacol. 4:2004;841-849
71. Singh, S. et al. (2001) An Indian herbal immunomodulator: highly effective in the treatment of HIV/AIDS. Proceedings of 6th International Conference on AIDS Asia Pacific, 5-10 October 2001, Melbourne, Australia (Abstract No. WePO 1254)
72. Grandhi A., et al. A comparative pharmacological investigation of Ashwagandha and Ginseng. J. Ethnopharmacol. 44:1994;131-135
73. Agarwal R., et al. Studies on immunoregulatory activity of Withania somnifera (Ashwagandha) extracts in experimental immune inflammation. J. Ethnopharmacol. 67:1999;27-35
74. Kulkarni R.R., et al. Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, crossover study. J. Ethnopharmacol. 33:1991;91-95
75. Chopra A., et al. Randomized double-blind trial of an Ayurvedic plant derived formulation for treatment of rheumatoid arthritis. J. Rheumatol. 27:2000;365-372
76. Kapil A., Sharma S. Immunopotentiating compounds from Tinospora cordifolia. J. Ethnopharmacol. 58:1997;89-95
77. Thatte U.M., et al. Tinospora cordifolia induces colony-stimulating activity in serum. J. Postgrad. Med. 40:1994;202-203
78. Nair R.P.K., et al. Immune-stimulating properties of a novel polysaccharide from the medicinal plant Tinospora cordifolia. Int. Immunopharmacol. 4:2004;1645-1659
79. Diwanay S.S., et al. Cytoprotection and immunomodulation in cancer therapy. Curr. Med. Chem. Anti-Canc. Agents. 4:2004;479-490
80. Tan B.K., Vanitha J. Immunomodulatory and antimicrobial effects of some traditional Chinese medicinal herbs: a review. Curr. Med. Chem. 11:2004;1423-1430
81. Burkhard H. Drugs from the deep: marine natural products as drug candidates. Drug Discov. Today. 8:2003;536-544
82. Waser S.P. Medicinal mushrooms as source of antitumor and immunomodulating polysaccharides. Appl. Microbiol. Biotechnol. 60:2002;258-274
83. Shao B.M., et al. Immune receptors for polysaccharides from Ganoderma lucidum. Biochem. Biophys. Res. Commun. 323:2004;133-141
84. Kim T.K. Chemical genomics and medicinal systems biology: chemical control of genomic networks in human systems biology for innovative medicine. J. Biochem. Mol. Biol. 37:2004;53-58
85. Song J.Y., et al. Induction of secretory and tumoricidal activities in peritoneal macrophages by ginsan. Int. Immunopharmacol. 2:2002;857-865
86. Chen B.J. Triptolide, a novel immunosuppressive and anti-inflammatory agent purified from a Chinese herb Tripterygium wilfordii Hook F. Leukemia and Lymphoma. 42:2001;253-265
87. Fritz P. Impact of mistletoe lectin binding in breast cancer. Anticancer Res. 24:2004;1187-1192
88. Sunila E.S., Kuttan G. Immunomodulatory and antitumor activity of Piper longum Linn and piperine. J. Ethnopharmacol. 90:2004;339-346
89. Liu M., et al. Advance in the pharmacological research on matrine. Zhongguo. Zhong Yao ZaY. 28:2003;801-804
90. Zhang L.H., et al. Several compounds from Chinese traditional and herbal medicine as immunomodulators. Phytotherapy Res. 9:1995;315-322
91. Yoon T.J., et al. Anti-metastatic activity of Acanthopanax senticosus extract and its possible immunological mechanism of action. J. Ethnopharmacol. 93:2004;247-253
92. Han S.B., et al. Toll-like receptor-mediated activation of B cells and macrophages by polysaccharide isolated from cell culture of Acanthopanax senticosus. Int. Immunopharmacol. 3:2003;1301-1312
93. Vanden W.E., et al. Effects of methoxylation of apocynin and analogs on the inhibition of reactive oxygen species production by stimulated human neutrophils. Eur. J. Pharmacol. 433:2001;225-230
94. Gautam M., et al. Immunoadjuvant potential of Asparagus racemosus in experimental system. J. Ethnopharmacol. 91:2004;251-255